Holen Sie sich die Stockscreener-App
30.42
0.16%
-0.05
Handel nachbörslich:
30.29
-0.13
-0.43%
Schlusskurs vom Vortag:
$30.47
Offen:
$30.22
24-Stunden-Volumen:
1.08M
Relative Volume:
0.45
Marktkapitalisierung:
$3.71B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$209.00M
KGV:
18.32
EPS:
1.6605
Netto-Cashflow:
$-94.86M
1W Leistung:
+5.70%
1M Leistung:
-5.73%
6M Leistung:
+33.83%
1J Leistung:
+232.46%
1-Tages-Spanne:
$29.76
$30.78
1-Wochen-Bereich:
$29.06
$31.25
52-Wochen-Spanne:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
30.42 | 3.71B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
INDV Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
INDV | Indivior Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
INDV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - stocktitan.net
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings - Sahm
Indivior Pharmaceuticals Inc. R (E7P.F) Insider Ownership & Holdings - Yahoo! Finance Canada
JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - marketbeat.com
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - Yahoo Finance UK
Indivior Pharmaceuticals Inc. R (E7P.F) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - msn.com
Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - Yahoo Finance UK
INDV Technical Analysis & Stock Price Forecast - Intellectia AI
What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
Indivior Pharmaceuticals, Inc - Reuters
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine - National Today
New Cost Model Shows Monthly Injectable Buprenorphine Can Reduce Staffing Burdens in Prisons - National Today
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - The Manila Times
Monthly opioid addiction shot may cut jail staffing, model estimates - stocktitan.net
Zacks.com spotlights Indivior, Ciena, and Ultra Clean as notable mentions - Bitget
Zacks.com featured highlights include Indivior, Ciena and Ultra Clean - Yahoo Finance
New Model Puts Indivior’s SUBLOCADE Correctional Opportunity In Focus - Sahm
Indivior Pharmaceuticals Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsINDV - GuruFocus
Indivior PLC (NASDAQ:INDV) Short Interest Up 21.7% in March - marketbeat.com
Indivior: Still Attractive After FY25 Earnings Beat (NASDAQ:INDV) - Seeking Alpha
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its 200% One Year Surge? - simplywall.st
Hennion & Walsh Asset Management Inc. Purchases 96,177 Shares of Indivior PLC $INDV - marketbeat.com
SG Americas Securities LLC Buys 363,829 Shares of Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - MarketScreener
Indivior (INDV) posts 2025 growth, SUBLOCADE gains and $400M buyback in 2026 proxy - Stock Titan
Suboxone Market Size Forecasts 2026-2033: Analyzing Industry - openPR.com
Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus - AD HOC NEWS
Indivior Pharmaceuticals Inc (INDV) Shares Up 5.07% on Mar 25 - GuruFocus
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Down 12.9% Over the Past Month: Reasons to Consider Purchasing Indivior Pharmaceuticals Inc. (INDV) During the Decline - Bitget
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
[SCHEDULE 13G] Indivior Pharmaceuticals, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Indivior Pharmaceuticals to report Q4 earnings: What's in the cards? - MSN
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Weakness - Sahm
Implied volatility surging for Indivior Pharmaceuticals stock options - MSN
Indivior Pharmaceuticals Inc (INDV) Shares Gap Down to $29.44 on Mar 20 - GuruFocus
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Indivior Pharmaceuticals Inc-Aktie (INDV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kingsley Stuart A | Director |
Mar 06 '26 |
Buy |
31.86 |
940 |
29,953 |
5,582 |
| Ryan Barbara | Director |
Mar 09 '26 |
Buy |
32.56 |
31 |
1,009 |
5,716 |
| Ryan Barbara | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
1,963 |
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):